Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Mirvetuximab soravtansine (IMGN853), an antibody-drug conjugate (ADC), integrates the cytotoxic agent DM4 with the humanized monoclonal antibody M9346A through a covalent bond. This compound targets folate receptor 1 (FOLR1) with specificity and exerts an anti-proliferative impact by inducing growth arrest and enhancing DNA damage [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Mirvetuximab soravtansine (IMGN853), an antibody-drug conjugate (ADC), integrates the cytotoxic agent DM4 with the humanized monoclonal antibody M9346A through a covalent bond. This compound targets folate receptor 1 (FOLR1) with specificity and exerts an anti-proliferative impact by inducing growth arrest and enhancing DNA damage [1]. |
In vitro | Mirvetuximab soravtansine (IMGN853; 8 nM; 6 h; IGROV-1 cells) combined with Carboplatin enhances synergistic growth inhibition and cell cycle disruption in vitro [1]. |
In vivo | Mirvetuximab soravtansine (IMGN853; 5 mg/kg; i.v.; SCID female mouse xenograft models derived from patients) enhances the in vivo antitumor activity of Carboplatin [1]. |
Synonyms | IMGN853 |
Molecular Weight | N/A |
CAS No. | 1453084-37-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Mirvetuximab soravtansine 1453084-37-1 IMGN853 IMGN-853 IMGN 853 inhibitor inhibit